Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boehringer Ingelheim buys Pharmaxis NASH candidate

This article was originally published in Scrip

Executive Summary

Boehringer Ingelheim is to pay €27.5m up front plus upwards of €500m in milestones to acquire a Phase I candidate that has shown preclinical promise in non-alcoholic steatohepatitis (NASH) from Pharmaxis. The German company is exercising an option that it already held to acquire the investigational drug PXS4728A, a semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) inhibitor that is designed to block leucocyte adhesion and tissue infiltration in inflammatory processes.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts